Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Shannon M BuckleyDepartment of Internal Medicine, Division of Hematology & Hematopoietic Malignancies, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0002-0523-2893
Sandipan BrahmaFred and Pamela Buffet Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
M Jordan RowleyFred and Pamela Buffet Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
R Katherine HydeDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA. kate.hyde@unmc.edu.ORCID http://orcid.org/0000-0003-2808-1749
Funding
UNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Heather Colleen Jensen-Smith · 2012 to 2026
$59.2M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 1985 to 2026
$55.0M
Target Validation CoreP20GM121316 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ADRIAN R BLACK · 2018 to 2026
$23.5M
Translational Imaging and Behavioral Assessment (TIBA) CoreP20GM130447 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Anna Dunaevsky · 2020 to 2026
$20.7M
CHEMICAL CARCINOGENESIS &CANCER BIOLOGYT32CA009476 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Jennifer D. Black · 1988 to 2026
$6.2M
Research Pilot Project ProgramP30GM106397 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI JOHNSON, KEITH R · 2013 to 2017
$4.9M
Fine-Scale Genome Folding Relative to Transcription and LocationR35GM147467 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Michael Jordan Rowley · 2022 to 2026
$2.0M
The Role of the CBFB-MYH11 Complex in Leukemia MaintenanceR01CA244900 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI HYDE, RICIA KATHERINE · 2020 to 2024
$1.9M
Genome-wide mechanisms and dynamics of ATP-dependent chromatin remodeling complexesR00GM138920 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BRAHMA, SANDIPAN · 2023 to 2025
$747k
Light-Sheet Fluorescence MicroscopeS10OD030486 · OD · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI JENSEN-SMITH, HEATHER COLLEEN · 2021 to 2021
Runt-related Transcription Factor 1 (RUNX1) is essential for definitive hematopoiesis and is among the most frequently mutated genes in leukemia. Previous work from our lab demonstrated that Histone Deacetylase 1 (HDAC1), a known RUNX1 partner, is unexpectedly required for active transcription suggesting a non-histone role for HDAC1 in regulating components of the RUNX1 complex. Here, we use proteomics, genomics, and long-read transcriptomics to identify novel RUNX1 interacting partners and decipher their role in gene regulation and RNA splicing in leukemia cells. We demonstrate that Polypyrimidine Tract Binding Protein 1 (PTBP1) interacts with RUNX1 in an HDAC1-dependent manner. Chromatin profiling revealed extensive genome-wide overlap in sites occupied by RUNX1 and PTBP1, with significant enrichment at promoters of actively transcribed genes. Loss of PTBP1 in AML cells led to widespread alterations in RNA splicing and decreased expression of genes whose promoters are bound by both factors, including metabolic genes. In agreement with these findings, we found that loss of PTBP1 reduced glycolysis and glucose uptake and ultimately caused cell death. Based on our data, we propose that the interaction between RUNX1 and PTBP1 facilitates expression of metabolic proteins essential for leukemia cell growth and survival.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
The splicing factor PTBP1 interacts with RUNX1 and is required for leukemia cell survival. · full record | Socratic